Octreotide implant having a release agent and uses thereof

Details Octreotide implant having a release agent and uses thereof Octreotide implant having a release agent and uses thereof

2011-06-14

2011-06-14

Landsman, Robert (Department: 1646)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S021700, C424S422000, C424S460000

Reexamination Certificate

active

07960335

ABSTRACT:
Methods, formulations and kits are described that allow for the controlled release of octreotide, e.g., octreotide acetate, in a subject.

REFERENCES:
patent: 2513014 (1950-06-01), Fields
patent: 3921632 (1975-11-01), Bardani
patent: 4131604 (1978-12-01), Szycher
patent: 4285987 (1981-08-01), Ayer et al.
patent: 4298002 (1981-11-01), Ronel et al.
patent: 4386039 (1983-05-01), Szycher
patent: 4523005 (1985-06-01), Szycher
patent: 4743673 (1988-05-01), Johnston et al.
patent: 4751133 (1988-06-01), Szycher et al.
patent: 4846793 (1989-07-01), Leonard et al.
patent: 4871094 (1989-10-01), Gall et al.
patent: 4954587 (1990-09-01), Mueller
patent: 4959217 (1990-09-01), Sanders et al.
patent: 4994028 (1991-02-01), Leonard et al.
patent: 5004614 (1991-04-01), Staniforth
patent: 5035891 (1991-07-01), Runkel et al.
patent: 5254662 (1993-10-01), Szycher et al.
patent: 5266325 (1993-11-01), Kuzma et al.
patent: 5273752 (1993-12-01), Ayer et al.
patent: 5292515 (1994-03-01), Moro et al.
patent: 5342622 (1994-08-01), Williams et al.
patent: 5354835 (1994-10-01), Blair
patent: 5431921 (1995-07-01), Thombre
patent: 5464933 (1995-11-01), Bolognesi et al.
patent: 5468811 (1995-11-01), Moro et al.
patent: 5614223 (1997-03-01), Sipos
patent: 5637309 (1997-06-01), Tajima et al.
patent: 5686411 (1997-11-01), Gaeta et al.
patent: 5756127 (1998-05-01), Grisoni et al.
patent: 5817343 (1998-10-01), Burke
patent: 5854127 (1998-12-01), Pan
patent: 5876761 (1999-03-01), Bodmer et al.
patent: 5894458 (1999-04-01), Takizawa et al.
patent: 6087334 (2000-07-01), Beeley et al.
patent: 6143718 (2000-11-01), Kolterman et al.
patent: 6159490 (2000-12-01), Deghenghi
patent: 6313254 (2001-11-01), Meijs et al.
patent: 6337318 (2002-01-01), Trigg et al.
patent: 6361797 (2002-03-01), Kuzma et al.
patent: 6417164 (2002-07-01), Kolterman et al.
patent: 6579851 (2003-06-01), Goeke et al.
patent: 6602694 (2003-08-01), Albrandt et al.
patent: 6770623 (2004-08-01), Chang et al.
patent: 6872700 (2005-03-01), Young et al.
patent: 6942264 (2005-09-01), Mendez
patent: 6969480 (2005-11-01), Dalton et al.
patent: 7008927 (2006-03-01), Ochiai et al.
patent: 7056887 (2006-06-01), Coolidge et al.
patent: 7101853 (2006-09-01), Young et al.
patent: 7105489 (2006-09-01), Hathaway
patent: 7115569 (2006-10-01), Beeley et al.
patent: 7118737 (2006-10-01), Kochendoerfer et al.
patent: 7153825 (2006-12-01), Young et al.
patent: 7220721 (2007-05-01), Beeley et al.
patent: 7259136 (2007-08-01), Hathaway et al.
patent: 7271238 (2007-09-01), Gaeta et al.
patent: 7452868 (2008-11-01), Kuzma et al.
patent: 2002/0141985 (2002-10-01), Pittner et al.
patent: 2003/0036504 (2003-02-01), Kolterman et al.
patent: 2004/0002454 (2004-01-01), Coolidge et al.
patent: 2004/0097419 (2004-05-01), Petersen et al.
patent: 2005/0037078 (2005-02-01), Kuo et al.
patent: 2005/0143303 (2005-06-01), Quay et al.
patent: 2005/0287320 (2005-12-01), Dalton et al.
patent: 2006/0019903 (2006-01-01), Kuzma et al.
patent: 2006/0030528 (2006-02-01), Hathaway et al.
patent: 2006/0035836 (2006-02-01), Coolidge et al.
patent: 2006/0067911 (2006-03-01), Nilsson et al.
patent: 2006/0122106 (2006-06-01), Gedulin et al.
patent: 2006/0148713 (2006-07-01), Beeley et al.
patent: 2006/0204540 (2006-09-01), Kuzma et al.
patent: 2006/0233747 (2006-10-01), Kochendoerfer et al.
patent: 2006/0293232 (2006-12-01), Levy et al.
patent: 2007/0010656 (2007-01-01), Beeley et al.
patent: 2008/0311170 (2008-12-01), Kuzma et al.
patent: 2009/0035343 (2009-02-01), Kuzma et al.
patent: 2009/0087470 (2009-04-01), Kuzma et al.
patent: 0 246 653 (1987-11-01), None
patent: 0 314 206 (1989-05-01), None
patent: 0 384 646 (1990-08-01), None
patent: 0 551 699 (1993-07-01), None
patent: 0 645 136 (1995-03-01), None
patent: 821383 (1937-12-01), None
patent: 1 306 541 (1973-02-01), None
patent: 05-269759 (1993-10-01), None
patent: 05-269760 (1993-10-01), None
patent: 07-097338 (1995-04-01), None
patent: 07-252166 (1995-10-01), None
patent: 11-506730 (1999-06-01), None
patent: 2002-535452 (2002-10-01), None
patent: 245383- (1994-05-01), None
patent: WO-96/40049 (1996-12-01), None
patent: WO-98/44964 (1998-10-01), None
patent: WO-00/44356- (2000-08-01), None
patent: WO-02/49573 (2002-06-01), None
patent: WO-02/078597 (2002-10-01), None
patent: WO-2004/071736 (2004-08-01), None
patent: WO-2005/013936 (2005-02-01), None
patent: WO-2005/041873 (2005-05-01), None
patent: WO-2006/099288 (2006-09-01), None
patent: WO-2007/028394 (2007-03-01), None
patent: WO-2008/061355 (2008-05-01), None
patent: WO-2008/134475 (2008-11-01), None
U.S. Appl. No. 12/490,971, filed Jun. 24, 2009, Kuzma et al.
“RxMed: Pharmaceutical Information-Sandostatin LAR DEPOT” [online], Jan. 6, 2003 [retrieved Aug. 16, 2006]; http://www.rxmed.com.
A.R. Gennaro, Remington: The Science and Practice of Pharmacy, 19th Edition, p. 1662, 1995.
Barradell, L. B. et al., “Histrelin: A Review of its Pharmacological Properties and Therapeutic Role in Central Precocious Puberty,” Drugs, vol. 45, No. 4, Apr. 1993, pp. 570-588; published by Adis International Limited.
Berge, et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Sciences, vol. 66, No. 1, Jan. 1977, pp. 1-19.
Bevan et al., Primary Medical Therapy for Acromegaly: An Open, Prospective, Multicenter Study of the Effects of Subcutaneous and Intramuscular Slow-Release Octreotide on Growth Hormone, Insulin-Like Growth Factor-L, and Tumor Size, J. Clin. Endoc. Metab,. 87(10), 2002, pp. 4554-4563.
Chinese Office Action corresponding to CN 2006800160292, dated Sep. 4, 2009, 8 pages.
Eurasian Patent Office Decision on Patentability corresponding to EU 200701956/28, dated Jan. 21, 2009, 6 pages.
New Zealand Patent Office Examination Report corresponding to NZ 561400, dated Jul. 28, 2009, 2 pages.
Feuillan, P. P. et al., “Follow-up of children and young adults after GnRH-agonist therapy for central precocious puberty,” J. Endocrinol. Invest., vol. 24, 2001, pp. 734-736; published by Editrice Kurtis.
Higuchi, et al., Pro-Drugs as Novel Drug Delivery Systems: A.C.S Symposium Series, American Chemical Society, Washington, DC, 1975.
International Search Report and Written Opinion, PCT/US2009/050215, dated Nov. 25, 2009, 11 pgs.
International Search Report, PCT/US00/01664, dated Jul. 13, 2000, 1 pg.
International Search Report, PCT/US06/08891, dated Dec. 4, 2006, 2 pgs.
International Search Report, PCT/US2005/021368, dated Oct. 23, 2006, 3 pgs.
International Search Report, PCT/US2008/061511, dated Nov. 8, 2009, 2 pgs.
Lan NaLee, “Volume of Blood in a Human,” from http://hypertextbook.com/facts/1998/LanNaLee.shtml, (1998) updated (2001).
Langer, “Implantable Controlled Release Systems,” Pharmac. Ther. (1983), vol. 21, p. 35-51.
P. Kuzma et al., U.S. PTO Office Action, U.S. Appl. No. 11/155,822 dated Jan. 22, 2008, 12 pgs.
P. Kuzma et al., U.S. PTO Office Action, U.S. Appl. No. 11/155,822 dated Feb. 18, 2009, 11 pgs.
P. Kuzma et al., U.S. PTO Office Action, U.S. Appl. No. 11/155,822 dated Oct. 13, 2009, 21 pgs.
Palii et al., “Medical treatment of diabetic retinopathy with somatostatin analogues,” Expert Opinion Investig. Drugs, vol. 16, No. 1, (2007), pp. 73-82.
Pawlikowski et al., “Perspectives of new potential therapeutic applications of somatostatin analogs,” Neuroendocrinology Letters, vol. 24, Nos. 1/2, Feb.-Apr. 2003, pp. 21-27.
Pierard-Franchimont et al., “Incidental Control of Rosacea by Somatostatin,” Dermatology, (2003) 206:249-251.
Roche, ed., Bioreversible Carriers in Drug Design: Theory and Application, Pergamon Press, New York, 1987.
American Peptide Company, Inc., Peptide Catalog 2006-2007, pp. 119, 171, 175, 211, 217, 219, 227, 296, 315, 317 and 329.
Bodmer D., et al: “Factors influencing the release of peptides and proteins from biodegradable parenteral depot systems” Journal of Controlled Release, Elsevier, Amsterdam, NL LNKD- DOI:10.1016/0168-3659(92)90014-I, vol. 21, No. 1-3, Jul. 1, 1992 , pp. 129-137, XP025702099 ISSN: 0168-3659 [retrieved on Jul. 1, 1992].
E

Affiliated with

Also associated with

Rating

Octreotide implant having a release agent and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Octreotide implant having a release agent and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Octreotide implant having a release agent and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2675556